EUVIMEDEUVIMED entdecken
Crossref

Lansoprazole (LPZ) reverses multidrug resistance (MDR) in cancer through impeding ATP-binding cassette (ABC) transporter-mediated chemotherapeutic drug efflux and lysosomal sequestration

Ning Ji, Hui Li, Yixuan Zhang, Yuelin Li, Peiyu Wang, Xin Chen, Yi-Nan Liu, Jing-Quan Wang, Yuqi Yang, Zhe-Sheng Chen, Yueguo Li, Ran Wang und 1 weitere

Drug Resistance Updates · 2024-09 · 76 · 101100

DOI: 10.1016/j.drup.2024.101100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2024-09. Verfasst von Ning Ji und 12 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University …. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily B, Drug Resistance, Multiple, Drug Resistance, Neoplasm, Lansoprazole. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: National Postdoctoral Program for Innovative Talents, China Postdoctoral Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Lansoprazole is one of the many proton pump inhibitors (PPIs) that acts more strongly with ABCB1 and ABCG2. The present study is to investigate the potential of lansoprazole on reversal of ABCB1/G2-mediated MDR in cancer, in vitro and in vivo. METHODS: Reversal studies and combination evaluation were conducted to determine the synergistic anti-MDR effects on lansoprazole. Lysosomal staining was used to determination of lansoprazole on ABCB1-mediated lysosomal sequestration. Substrate accumulation and efflux assays, ATPase activity, and molecular docking were conducted to evaluate lansoprazole on ABCB1/G2 functions. Western blot and immunofluorescence were used to detect lansoprazole on ABCB1/G2 expression and subcellular localization. MDR nude mice models were established to evaluate the effects of lansoprazole on MDR in vivo. RESULTS: Lansoprazole attenuated ABCB1/G2-mediated MDR and exhibited synergistic effects with substrate drugs in MDR cells. In vivo experiments demonstrated that lansoprazole attenuated ABCB1/G2-mediated MDR and exhibited synergistic effects that augmented the sensitivity of substrate anticancer drugs in ABCB1/G2-mediated settings without obvious toxicity. Lansoprazole impeded lysosomal sequestration mediated by ABCB1, leading to a substantial increase in intracellular accumulation of substrate drugs. The effects of lansoprazole were not attributable to downregulation or alterations in subcellular localization of ABCB1/G2. Lansoprazole promoted the ATPase activity of ABCB1/G2 and competitively bound to the substrate-binding region of ABCB1/G2. CONCLUSIONS: These findings present novel therapeutic avenues whereby the combination of lansoprazole and chemotherapeutic agents mitigates MDR mediated by ABCB1/G2 overexpression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ATP Binding Cassette Transporter, Subfamily BDrug Resistance, MultipleDrug Resistance, NeoplasmLansoprazoleLysosomesProton Pump InhibitorsAnimalsHumansMiceAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily G, Member 2Cell Line, TumorMice, NudeMolecular Docking SimulationNeoplasm ProteinsNeoplasmsXenograft Model Antitumor Assays

Stichwörter der Autor:innen

ABC transporterDrug effluxLansoprazoleLysosomal sequestrationMultidrug resistance in cancer (MDR)

Substanzen

ABCB1 protein, humanABCG2 protein, humanAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily G, Member 2LansoprazoleNeoplasm ProteinsProton Pump Inhibitors

Autor:innen und Institutionen

  • Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for C…
  • Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA.

Förderung

  • National Postdoctoral Program for Innovative Talents
  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Ji, N., Li, H., Zhang, Y., Li, Y., Wang, P., Chen, X., Liu, Y. N., Wang, J. Q., Yang, Y., Chen, Z. S., Li, Y., Wang, R., & Kong, D. (2024). Lansoprazole (LPZ) reverses multidrug resistance (MDR) in cancer through impeding ATP-binding cassette (ABC) transporter-mediated chemotherapeutic drug efflux and lysosomal sequestration. Drug Resistance Updates, 76, 101100. https://doi.org/10.1016/j.drup.2024.101100

Vancouver

Ji N, Li H, Zhang Y, Li Y, Wang P, Chen X, et al. Lansoprazole (LPZ) reverses multidrug resistance (MDR) in cancer through impeding ATP-binding cassette (ABC) transporter-mediated chemotherapeutic drug efflux and lysosomal sequestration. Drug Resistance Updates. 2024;76:101100. doi:10.1016/j.drup.2024.101100

BibTeX
@article{Ji2024,
  author = {Ji, Ning and Li, Hui and Zhang, Yixuan and Li, Yuelin and Wang, Peiyu and Chen, Xin and Liu, Yi-Nan and Wang, Jing-Quan and Yang, Yuqi and Chen, Zhe-Sheng and Li, Yueguo and Wang, Ran and Kong, Dexin},
  title = {Lansoprazole (LPZ) reverses multidrug resistance (MDR) in cancer through impeding ATP-binding cassette (ABC) transporter-mediated chemotherapeutic drug efflux and lysosomal sequestration},
  journal = {Drug Resistance Updates},
  year = {2024},
  volume = {76},
  pages = {101100},
  doi = {10.1016/j.drup.2024.101100}
}
Kostenlos starten →